Atlas Trials

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Clinical trial NCT00869323 · TERMINATED

Trial details

NCT number
NCT00869323
Sponsor
Masonic Cancer Center, University of Minnesota
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphoproliferative Disorder
Start date
2009-03-01
Primary completion
2013-03-01
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.